Galderma SA (Switzerland)

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global chemical peel market size is estimated to grow by USD 814.4 millionn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.19% during the forecast period. Increasing demand for aesthetic procedures and technological advancement is driving market growth, with a trend towards increasing awareness about anti-aging measures. However, high cost of chemical peel products poses a challenge. Key market players include AbbVie Inc., AMOREPACIFIC Group Inc., Bausch Health Companies Inc., BeautyPharmaCo, Candela Corp., Caudalie International SE, Galderma SA, Hale Cosmeceuticals Inc, Image International Manufacturing LLC, Johnson and Johnson Services Inc., LOreal SA, MedPeel, Merz Pharma GmbH and Co KGaA, NEFTIS LABORATORIOS SL, Pierre Fabre SA, ProDerma Light, Radius Healthcare Pvt. Ltd., Renee Rouleau Inc., Topix Pharmaceuticals Inc., and Unilever PLC. Continue Reading Technavio has announced its latest market research report titled Global chemical peel market 2024-2028 Get a detailed analysis on regions, market segments, customer landscape, and companies - Click for the snapshot of this report Key Market Trends Fueling Growth The chemical peel market is experiencing significant growth due to the increasing awareness and demand for anti-aging procedures. In 2021 and 2022, there has been a rise in the number of cosmetic procedures performed in countries like the US, Brazil, Mexico, Germany, and Spain. This trend is driven by the advantages of chemical peels, including age spot reduction, sun damage removal, skin lightening, smoothening, and improved collagen growth. Vendors are actively promoting these benefits through various channels, such as websites, conferences, and magazine advertisements. Moreover, the increasing per capita income and economic development in emerging economies, particularly India and China, have led to a surge in online research and comparisons of various procedures. As a result, the chemical peel market is poised for continued growth during the forecast period. The Chemical Peel Market is witnessing significant growth due to the increasing demand for non-surgical skincare solutions. Trichloroacetic acid and Jessner's Solution are popular peeling agents used in chemical resurfacing for improving skin texture, reducing hyperpigmentation, acne scars, fine lines, and wrinkle reduction. These treatments are effective for sun damage, melasma treatment, and acne treatment. Medical aesthetics and cosmeceutical treatments using chemical formulations offer clinical benefits for various skin conditions. Glytone, Alpha hydroxy acid (AHA), sugar cane, sugar beets, lactic peel, milk, and Alpha-hydroxy acids (AHAs) are common peeling agents. Medium peels target the epidermis and dermis layers for enhanced skin health and beauty. The chemical peel procedure is a dermatologic treatment for skin health improvement and aesthetic enhancement. Discover a Comprehensive 360° Market Analysis: Understand the Impact of AI. For detailed information- Request Sample! Market Challenges The chemical peel market is currently facing a growth challenge due to the high cost of treatments, which is limiting its adoption, particularly in developing countries. The average price for a chemical peel ranges from USD600 to USD900, with significant variations depending on the type of peel. Light peels cost as low as USD150 but require multiple sessions for optimal results, while medium and deep peels can cost up to USD6,000. These high costs include fees for the chemical peel procedure, anesthesia, and operating room. The monopolistic approach of vendors, such as Allergan plc, in the market further contributes to the lack of competitive pricing. Allergan, a leading player in medical aesthetics, has acquired most of the market share, targeting high-income and upper-middle-class consumers. As a result, the inability of middle and lower-middle-class individuals to afford these costly procedures is hindering the growth of the global chemical peel market. The Chemical Peel market is thriving in the Skincare and Aesthetics industries, providing solutions for common concerns such as Acne, Pigmentation, and Wrinkle issues. Glytone's Peeling Solution, which contains Alpha Hydroxy Acids (AHAs) derived from Sugar Cane and Sugar Beets, is a popular choice for exfoliating the Epidermis. Medium Peels, using stronger Chemical Agents like TCA, reach deeper into the Dermis to address Acne spots, Dark Circles, and signs of Fatigue. Dermatology and Aesthetic Medicine professionals use these Dermatological Procedures for Skin Renewal, often combining different Chemical Compounds like Glycolic Acid, Lactic Acid, and Salicylic Acid for optimal results. The Beauty Industry continues to innovate with new Peeling Solutions, offering professional Chemical Exfoliation treatments for Facial Rejuvenation. For more insights on driver and challenges - Download a Sample Report Segment Overview This chemical peel market report extensively covers market segmentation by End-user 1.1 Hospital and recreation centers 1.2 Dermatology clinics Type 2.1 Light peel 2.2 Medium peel 2.3 Deep peel Geography 3.1 North America 3.2 Europe 3.3 APAC 3.4 South America 3.5 Middle East and Africa 1.1 Hospital and recreation centers- The Chemical Peel Market is experiencing steady growth due to increasing consumer awareness and demand for skin rejuvenation treatments. Businesses are offering various types of chemical peels to cater to diverse skin concerns, such as acne scars, aging, and sun damage. Market leaders are focusing on research and development to introduce innovative peel solutions and expand their customer base. Overall, the market is expected to continue its expansion in the coming years.For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 - 2022) - Download a Sample Report Research Analysis The Chemical Peel market encompasses a range of skincare treatments used in aesthetics to address various skin concerns, including acne, pigmentation, and wrinkle issues. These peels work by applying a chemical solution to the skin, causing it to exfoliate and peel off, revealing smoother, fresher skin. The solutions typically contain Alpha-hydroxy acids (AHAs) derived from fruits like glycolic acid from sugar cane and lactic peels from milk. Deeper peels may involve Phenol or Trichloroacetic acid, reaching the dermis for more significant results. Acne spots, dark circles, and signs of fatigue can also be targeted. Genetics and collagen production play a role in skin health, making chemical peels a popular choice for those seeking to improve their complexion in dermatology practices. Market Research Overview The Chemical Peel market encompasses a range of skincare treatments that utilize chemical solutions to improve the appearance of the skin. These peels are commonly used for various aesthetic concerns such as acne, pigmentation, and wrinkle issues. The solutions typically contain Alpha Hydroxy Acids (AHAs) derived from fruits like sugar cane and sugar beets, or Beta Hydroxy Acids (BHAs) like Salicylic Acid. The depth of the peel can vary from light to medium, affecting the epidermis or dermis layers. Chemical Peels are used to address acne spots, dark circles, fatigue, and signs of aging such as fine lines and wrinkles. The causes of these conditions can stem from genetics, sun damage, or lifestyle factors. The treatments promote collagen production, leading to skin renewal and texture improvement. Chemical Peels are considered a dermatological procedure and are also offered in aesthetic medicine clinics and the beauty industry. They provide a form of chemical exfoliation that goes beyond traditional cleansing methods. The solutions work by dissolving the bonds holding dead skin cells together, revealing smoother, healthier skin. Popular chemical peel formulations include Glytone, Jessner's Solution, TCA Peel, and various combinations of AHAs and BHAs. These treatments are administered as facial treatments in professional settings and are an essential part of medical aesthetics and cosmeceutical offerings. Chemical Peels contribute to skin health and beauty enhancement, addressing various skin conditions and concerns. They are an effective means of reducing hyperpigmentation, acne scars, sun damage, and melasma. The cosmetic procedure is a popular choice for individuals seeking wrinkle reduction and skin rejuvenation. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation End-user Hospital And Recreation Centers Dermatology Clinics Type Light Peel Medium Peel Deep Peel Geography North America Europe APAC South America Middle East And Africa 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepoints for the entire 12-month study period Evolus dermal filler, Evolysse™ Smooth, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at 6 and 9 months The safety profiles were similar between the two Evolysse™ dermal filler products and Restylane-L and there were no treatment-related serious adverse events On track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our Premarket Approval application for the U.S. launch of our dermal filler lines. Complementing our flagship neurotoxin Jeuveau® – the fastest growing neurotoxin in the U.S. for the past three years1 – our Evolysse™ line of dermal fillers expands our total addressable market by 78%,” said David Moatazedi, President and Chief Executive Officer. “Built on the earlier success of the European head-to-head trial, the consistency of results from this pivotal trial for Evolysse™ Lift and Smooth were impressive when compared to the previously shared European nasolabial fold data,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. “The R&D team remains on track to complete and submit the PMA to the FDA within the next 90 days and this data increases our confidence in the submission.” “As an investigator in this pivotal trial, I had first-hand experience in treating patients with the new Evolysse™ HA filler line that is manufactured using a novel “Cold Technology” process which is aimed at preserving the natural structure of the HA molecule,” said Dr. Steven Dayan, MD. “Clinically, I found the product to be precise and I could treat patients to optimal correction. I was also struck by the fact that despite using the same amount of product between the treatment and control, there seems to be more of a difference in the correction when looking at the Evolysse™ treatment arm.” Study Design The U.S. NLF pivotal study was a multicenter, blinded, split face, controlled, non-inferiority design. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse™ Lift or Evolysse™ Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse™ fillers and the control at the same time. The 6-month primary endpoint measured the change in NLF severity from baseline and was assessed by a blinded independent photographic review panel using a validated 5-point nasolabial scale. Results The Evolysse™ Lift vs Restylane-L arm met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.3 (95% CI: -0.500, -0.032, non-inferiority margin 0.5) and corresponding p-value of 0.03. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at all timepoints from 6 weeks to 12 months between Evolysse™ Lift and the control. The Evolysse™ Smooth vs Restylane-L arm also met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.2 (95% CI: -0.416, -0.019, non-inferiority margin 0.5) and corresponding p-value of 0.02. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at 6 and 9 months between Evolysse™ Smooth and the control. The safety profiles were similar between the two Evolysse™ dermal filler products compared to their respective controls and there were no treatment-related serious adverse events. Evolus remains on track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days. The Evolysse™ Lift filler will be positioned as the most versatile and highest use filler in the product line. The Evolysse™ Smooth filler is a softer product than Lift, providing additional versatility. 1 Measured by comparing year-over-year revenue growth of each aesthetic neurotoxin on the market for the entirety of each comparable year. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at , and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company’s forward-looking statements include, but are not limited to, statements related to anticipated product launches; market size, conditions and consumer demand; and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K Form and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 7, 2024. These filings can be accessed online at . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese Aesthetics S.A.S. Restylane® is a trademark of Galderma S.A.

World-leading CDMO Offers Highly Specialized Experience Bringing Complex Formulations to Market Quickly and Will Support Clinical Trials of Aldena’s siRNA-based Injectable Treatment PHILADELPHIA--(BUSINESS WIRE)-- Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI), a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility. ALD-102 is currently in preclinical trials and represents the most advanced therapy in Aldena's pipeline. Dermatological diseases affect more than 900 million people worldwide. Significant advancements in the treatment of various skin conditions and disorders have been made. However, there are still limitations and challenges in the field. With the siRNA-based approach, Aldena develops advanced and long-lasting treatments for skin conditions. CDMOs are playing a critical role in the large and small- medium pharmaceutical value chain, to bring these life-changing therapies to patients. “We are very pleased as Aldena’s agreement with PCI has given us the integrated services and support we need to meet our ambitious research and development timelines,” said Thibaud Portal, Ph.D., CEO of Aldena. “This collaboration with PCI will be essential as we continue building our pipeline of new dermatological products targeting conditions for which there is an unmet medical need.” PCI specializes in development and manufacturing, clinical trial services, advanced drug delivery and commercial technology services. Aldena chose PCI because of its expertise in complex formulations, and cold chain. PCI’s state-of-the-art robotic sterile fill-finish gloveless isolator platform can be used to fill various sterile medications into vials and syringes for small-to-mid size client needs. The equipment, paired with PCI’s end-to-end services and global network, comprises PCI’s Speed to Study™ offering, which drastically decreases the average turnaround time from proposal signing to the injectable product’s distribution for clinical trial use. The Microcell Vial Filler and SA25 Aseptic Filling Workcell at PCI’s San Diego facility ensures the delivery of medicines from phase I through phase III, supporting local and global Clinical client needs. These advanced machines expedite the filling process with automation and remove the need for human intervention in a sterile environment, creating compliance advantages over standard equipment. While there is increased demand for siRNA-based therapies in the pharmaceutical industry, only highly specialized CDMOs like PCI can manage the unique handling requirements of fragile large-molecule formulas to manufacture them safely and efficiently. “We are proud to be one of only a few CDMOs worldwide able to offer integrated sterile fill-finish capabilities, alongside our clinical packaging facilities, to clients who are developing novel and disruptive approaches to treating disease,” said Salim Haffar, CEO of PCI Pharma Services. “Working with innovative companies like Aldena directly ladders back to our mission to provide clinical and commercial supply chain solutions to ultimately improve patients’ lives.” To better support its clients throughout the world, PCI has recently invested in expansions in Rockford, IL, and Tredegar, Wales, as well as established new facilities in Bedford, NH, and Boston, MA. About Aldena Aldena Therapeutics is a Boston, Lausanne, and London-based biotechnology company focusing on siRNA-based treatments for patients suffering from dermatological diseases. The Company was co- founded by Prof. John Harris (MD, PhD, Professor and Chair of Dermatology at UMass Chan Medical School), Prof. Mark Prausnitz (PhD, Regents' Professor at Georgia Institute of Technology) and Dr Andrew Tadros (MD, PhD) and is backed by international investment firm, Medicxi. Aldena Therapeutics has been led since its inception by dermatology specialist, CEO, Thibaud Portal, PhD, who previously led the Prescription Medicines business and strategy of Galderma SA after several senior R&D roles and co- founded several dermatology focused start-up companies. Aldena is pursuing multiple innovative programs and is currently initiating the IND-enabling GLP nonclinical program for its lead projects. About PCI Pharma Services PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 5,000 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. For more information, please visit pci.com View source version on businesswire.com: Contacts Ty Guzman-Touchberry, WE Communications tgtouchberry@we-worldwide.com / +1-212-551-4877 Source: PCI Pharma Services View this news release online at: